Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Kineta Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KA
Nasdaq
8731
https://kinetabio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Kineta Inc
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
- Apr 8th, 2024 8:01 pm
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
- Mar 21st, 2024 8:02 pm
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
- Mar 12th, 2024 12:00 pm
Kineta Announces Restructuring and Exploration of Strategic Alternatives
- Feb 29th, 2024 1:30 pm
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
- Feb 22nd, 2024 1:30 pm
Kineta to Present at Upcoming Investor Conferences
- Feb 14th, 2024 1:30 pm
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series
- Feb 7th, 2024 1:30 pm
KA: Phase I/II Update
- Jan 29th, 2024 9:32 am
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
- Jan 17th, 2024 1:30 pm
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
- Jan 4th, 2024 1:30 pm
Life Science Investor Forum: Presentations Now Available for Online Viewing
- Dec 15th, 2023 1:35 pm
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer
- Dec 13th, 2023 1:30 pm
Life Science Investor Forum Agenda Announced for December 14th, 2023
- Dec 12th, 2023 6:02 pm
Kineta to Present at the Life Sciences Investor Forum December 14th
- Dec 12th, 2023 2:24 pm
Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023
- Nov 28th, 2023 1:30 pm
Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit
- Nov 9th, 2023 1:30 pm
KA: Third Quarter Results
- Nov 7th, 2023 10:00 am
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
- Nov 6th, 2023 1:30 pm
Kineta Insider Purchases Yet To Pay Off Regardless Of Recent Strength
- Nov 4th, 2023 12:40 pm
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 3rd, 2023 8:01 pm
Scroll